SyncThink rebrands as NeuroSync in bid for market growth

Neurotechnology company SyncThink will rebrand the company as NeuroSync, as it looks to grow its stance in the neurological health market. 

With a new executive team, new products delivered and others under development, NeuroSync embarks upon accelerating its traction in the larger Neuro Healthcare landscape. In doing so, NeuroSync will leverage its position with EYE-SYNC’s core technology, its IP portfolio, array of clinical publications, and the patient data it has accumulated through prior and ongoing clinical studies.

Chairman and CEO Gary Gregory said: “NeuroSync represents a new chapter for our company. It is a strong reflection of what we have built and where we are headed in delivering diagnostic and therapeutic solutions for neuro health disorders around the world. Our proven ability to deliver objective and actionable data to providers, while expanding accessibility and outcomes for patients, positions us to transform the neuro health arena. With our technology platform, clinical position, and value driven solutions, we are extremely enthused about the runway before us, as we relaunch the company and strategic direction under NeuroSync.”

Founder and CSO Jam Ghajar, added: “Our evolution to NeuroSync highlights the bright future and vision of the company, while paying respect to our rich history of discovery and innovation. To that end, we felt that preserving the “Sync” in our name serves as a nod to both our past and future, while also accurately representing our proprietary synchronisation metrics, AI and analytics.”

In February, NeuroSync was chosen as a healthcare partner of Augmented Reality (AR) leader Magic Leap, where they will co-develop a platform for vestibular disorders. In August, EYE-SYNC received CE mark certification to commercialise efforts into Europe. Currently, NeuroSync is sponsoring ongoing clinical studies toward the development of a biomarker identification platform for Attention Deficit Hyperactivity Disorder (ADHD), further expanding the reach and impact of its technology platform across the neuro health market.

“The days of the imprecise diagnosis and treatment plan are over. Neurological providers and patients deserve better tools for better outcomes,” said Gregory. “And, that’s exactly what we are going to deliver.”